tiprankstipranks
Marker Therapeutics (MRKR)
NASDAQ:MRKR
US Market
MRKR
Marker Therapeutics
RESEARCH TOOLSreports
Want to see MRKR full AI Analyst Report?

Marker Therapeutics (MRKR) Stock News & Sentiment

604 Followers
Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained
3d ago
MRKR
MRKR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
MRKR Upcoming Earnings Report: What to Expect?
4d ago
MRKR
Marker Therapeutics Shareholders Approve Governance and Capital Changes
Premium
Company Announcements
Marker Therapeutics Shareholders Approve Governance and Capital Changes
17d ago
8K
MRKR
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
Premium
Ratings
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
2M ago
MRKR
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
Premium
Company Announcements
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
2M ago
MRKR
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
Premium
Ratings
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
2M ago
MRKR
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
2M ago
MRKR
More MRKR News >

MRKR News on the Web

MRKR Upcoming Earnings Report: What to Expect?
TipRanks News
Neutral
Marker Therapeutics Shareholders Approve Governance and Capital Changes
TipRanks News
Neutral
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
TipRanks News
Bullish
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
TipRanks News
Bearish
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
TipRanks News
Bullish
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
Zacks
Neutral
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
TipRanks News
Neutral
H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
MRKR
Sector Average
Media Buzz
This Week3 articles
Weekly Average0.25 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MRKR’s Media Buzz Sentiment?
3 articles about MRKR were published this week. In an average week, 0.25 articles are published.
    What is MRKR’s weekly average amount of articles?
    In an average week, 0.25 articles about MRKR are published.
      What is MRKR’s News Sentiment?
      100% of articles about MRKR were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        IMVTImmunovant
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        Showing the stocks with the most bullish news sentiment over the past week